3D cardiac mapping technology developer CardioInsight Technologies has closed on $7.5 million in Series C financing.
CardioInsight will use the proceeds to help accelerate clinical and commercial efforts related to its ECVue 3D cardiac mapping system, which generates real-time, whole-heart images of electrical activity by combining body-surface electrical data with 3D anatomical data obtained from imaging scans, according to the vendor.
CardioInsight recently received the European CE Mark and has installed ECVue at its first clinical customer sites, the company said. It will focus in the coming months on obtaining U.S. Food and Drug Administration regulatory clearance.
